Clinical Characteristics and Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Replacement Stratified by TRISCEND II Trial Eligibility
Recommended Citation
Razmjou S, Sundaralingam S, Bowerman N, Fram G, Dawdy J, Frisoli T, Lee J, Villablanca PA, O’Neill B, Engel Gonzalez P. Clinical Characteristics and Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Replacement Stratified by Triscend Ii Trial Eligibility. J Soc Cardiovasc Angiogr Interv. 2026;5(4).
Document Type
Article
Publication Date
4-1-2026
Publication Title
J Soc Cardiovasc Angiogr Interv
Abstract
BACKGROUND: Clinical trials for transcatheter tricuspid valve replacement (TTVR) use strict eligibility criteria that often exclude real-world patients, who may have more advanced disease and different outcomes. We compared characteristics and short-term results between patients who would have been eligible versus noneligible for the TRISCEND II trial.
METHODS: We analyzed a single-center cohort of 112 patients undergoing TTVR for symptomatic tricuspid regurgitation (TR). Patients were stratified according to TRISCEND II inclusion and exclusion criteria. Baseline demographics and 30-day outcomes were compared between eligible (n = 47) and noneligible (n = 65) groups.
RESULTS: Eligible patients were older (83.2 years [IQR, 77.4-86.7] vs 76.3 years [IQR, 69.6-83.1]), while sex distribution and New York Heart Association (NYHA) class III/IV were similar (female: 68.1% vs 64.6%; NYHA III/IV: 76.6% vs 75.4%). TR severity was comparable. Noneligible patients had lower ejection fraction (56% vs 60%) and more prior heart failure hospitalizations (13.8% vs 4.3%). At 30 days, both groups showed significant TR reduction, but noneligible patients remained more symptomatic (NYHA III/IV: 31.0% vs 11.9%) and had lower Kansas City Cardiomyopathy Questionnaire scores (65.63 vs 70.83). All-cause mortality (8.2% vs 2.0%) and major bleeding (17% vs 12.3%) were numerically higher in the noneligible group, whereas stroke, pacemaker implantation, and reintervention rates were low and similar.
CONCLUSIONS: Eligible patients had better cardiac function and were less symptomatic post-TTVR. Noneligible patients remained more symptomatic despite similar TR reduction, highlighting the need to consider real-world patient complexity when interpreting trial outcomes.
PubMed ID
42111092
Volume
5
Issue
4
First Page
104385
Last Page
104385
